Recruiting

Testing two medications together for difficult-to-treat T-cell lymphoma

Plain-English translation of NCT05313243 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This clinical trial is testing whether combining two medications— and —can help treat T-cell lymphoma that has returned or stopped responding to previous treatments. T-cell lymphoma is a rare blood cancer that is often aggressive and hard to treat. This study wants to see if the medication combination works better than what doctors currently have available.

Most patients with relapsed or refractory T-cell lymphoma have limited treatment options, and current medications only work for about 20–30% of patients. Many who do respond initially relapse again. This trial exists to test whether this new treatment approach using two targeted medications together can help more patients and keep their cancer under control longer.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with T-cell lymphoma that has come back or stopped responding to at least one prior treatment
your cancer cells have a marker called CD30 (confirmed by a previous biopsy)
you are in good enough overall health to handle the treatment (ECOG performance status 0–1)
you are willing to use contraception during treatment and for 4 months after your final dose if you can have children

You likely don't qualify if…

you have previously received immunotherapy drugs that work on PD-1, PD-L1, or similar immune checkpoints
you have adult T-cell leukemia/lymphoma (ATLL), a specific subtype
you have received cancer treatment within the past 4 weeks before starting the study
you are pregnant or breastfeeding

What participation looks like

You would receive intravenous infusions of two medications together for up to 16 treatment cycles, followed by additional cycles of one medication alone, for a total of about 35 doses of . The full treatment course spans many months. Throughout the study, you would have regular blood tests and scans to monitor how your cancer is responding and to check for any side effects from the medications.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Testing two medications together for difficult-to-treat T-cell lymphoma

What is this trial?

Do you qualify?

What participation looks like

Trial locations